##### 



EXHIBIT 10.01
 [Execution Copy]
 LICENSE AND SUPPLY AGREEMENT
 st
 WITNESSETH:
        Page 1 of 46




---



##### 



ARTICLE I  DEFINITIONS
 Affiliate
   Page 2 of 46




---



##### 



ARA
  Designee
 DHA
   Growing Up Milk Product GUM
 Infant Formula Product
 LCPUFA
 Licensed Patents Exhibit 1
   Page 3 of 46




---



##### 



Licensee Product
 Martek Products
 New Affiliates
  Other Product
 Specifications Exhibit 2
 Technology
   Page 4 of 46




---



##### 



Territory Exhibit 3
 Third Party
 Unit of Martek Products
  ARTICLE II  GRANT OF LICENSE AND OTHER RIGHTS
 License
     Page 5 of 46




---



##### 



Transfer of the Martek Products
 Sublicensing
 Trademarks
 Territory Expansion Exhibit 3
   Page 6 of 46




---



##### 



Collaboration Exhibit 4
 Special Circumstances with respect to New Affiliates
 ARTICLE III  PURCHASE AND SUPPLY OF THE MARTEK PRODUCTS
 Purchase of Martek Products
   Page 7 of 46




---



##### 



Exhibit 4
 Forecasts, Supply and Orders
 Exhibit 4 Exhibit 4
    Page 8 of 46




---



##### 



Order and Delivery Terms
     Page 9 of 46




---



##### 



Exhibit 2
 ARTICLE IV  TERM AND TERMINATION
 Term th Term
 Termination in Case of Material Breach; Opportunity to Cure
 Termination in Case of Infringement
   Page 10 of 46




---



##### 



Termination in Case of Insolvency; Government Action
 Early Termination by Licensee
 Effect of Termination
 Other Rights and Remedies; Limitation of Liability
   Page 11 of 46




---



##### 



ARTICLE V  PAYMENTS BY LICENSEE
 License Fee and Pre-Payment
 Product Pricing
 Exhibit 4 Exhibit 4 Exhibit
4
    Page 12 of 46




---



##### 



Payment Terms and Guarantee Exhibit 4
   Page 13 of 46




---



##### 



Other Pricing Issues
   Taxes
 Sample Analysis
   Page 14 of 46




---



##### 



Commercialization Expenses
 ARTICLE VI  REPRESENTATIONS AND WARRANTIES
 Marteks Representations and Warranties
    Marteks Disclaimers.
    Page 15 of 46




---



##### 



Licensees Representations and Warranties
   Licensees Disclaimer.
   Page 16 of 46




---



##### 



ARTICLE VII  LICENSEES COVENANTS
 Compliance with Law; Regulatory Approval
 Performance and Product Quality
   Page 17 of 46




---



##### 



Records
   Protection of Marteks Proprietary Interest
   Page 18 of 46




---



##### 



Product Use
 ARTICLE VIII  PATENT PROSECUTION AND ENFORCEMENT
 Patent Applications
 Infringement Notice
 Infringement Actions
 Defense of Infringement Actions
   Page 19 of 46




---



##### 



ARTICLE IX  ASSIGNMENT
 Assignment
 ARTICLE X  PARTIES RELATIONSHIP
 Relationship between Parties
 ARTICLE XI  INDEMNITY
 Indemnity by Licensee
   Page 20 of 46




---



##### 



Indemnity by Martek
 Condition to Indemnification
 Survival of Indemnity Obligation
   Page 21 of 46




---



##### 



ARTICLE XII  CONFIDENTIALITY
 Disclosure of Information
 Exhibit 5
   Page 22 of 46




---



##### 



Post-Term Obligations
 ARTICLE XIII  LIMITATION OF LIABILITY
 Indirect Damages
   Page 23 of 46




---



##### 



Exclusive Liability
 Maximum Aggregate Liability
 ARTICLE XIV  MISCELLANEOUS
 Dispute Resolution
   Page 24 of 46




---



##### 



Product Liability Insurance *
 Information Exchange
 Reciprocal Waiver
   Page 25 of 46




---



##### 



Force Majeure
 Construction of Agreement
 Notices
 
   Page 26 of 46




---



##### 



Entire Agreement
 Binding Effect
   Page 27 of 46




---



##### 



Counterparts
 Severability
 Waiver
 Survival
 Headings
 Expenses
   Page 28 of 46




---



##### 



MARTEK BIOSCIENCES CORPORATION (Martek)
    
    Numico Beheer B.V. (Licensee)By:
    
    
    
    By:Print Name:
    
    
    
    Print Name:Print Title:
    
    
    
    Print Title:Date:
    
    
    
    Date:
   Page 29 of 46




---



##### 



EXHIBIT 1  LICENSED PATENTS  (as of December 2007)
 Microbial Oil Mixtures and Uses Thereof
 Country
    
    Application No.
    
    Publ. or Patent No.
    
    StatusAustralia
    
    AU92/12392
    
    661,297
    
    Granted 7 Nov 95*
    
    *
    
    
    
    *Canada
    
    2,101,274
    
    2,101,274
    
    Granted 15 Dec 98Europe
    
    07002670.3
    
    EP1 787 532 A1
    
    Published 23 May 07(designates Austria, Belgium,
    
    
    
    (Div of EP1 092 352)Denmark, France, Germany,Greece, Italy, Luxembourg,
    
    07075341.3
    
    EP1 832 181 A2
    
    Published 12 Sep 07Monaco,
Netherlands, Spain,
Sweden,
Switzerland/
Liechtenstein, and
United Kingdom)
    
    
    
    (Div of EP1 092 352)Indonesia
    
    P001678
    
    ID 0000174
    
    Granted 20 Jun 95Israel
    
    100733
    
    100733
    
    Granted 1 Apr 96114253
    
    114253
    
    Granted 14 Oct 97Mexico
    
    9200320
    
    183638
    
    Granted 6 Jan 97New Zealand
    
    241359
    
    241359
    
    Granted 16 Feb 95Philippines
    
    43812
    
    1992-43812
    
    Granted 23 Nov 01Russia
    
    93052410.13
    
    2,093,996
    
    Granted 27 Oct 97Singapore
    
    9608986.7
    
    49307
    
    Granted 10 Jan 02(Revocation Pending)South Africa
    
    92/0452
    
    92/0452
    
    Granted 28 Oct 92South Korea
    
    1993-0702205
    
    321543
    
    Granted 9 Jan 022000-7003480
    
    292103
    
    Granted 20 Mar 01(Revocation Pending)Sri Lanka
    
    10526
    
    10526
    
    Granted 17 Jun 94United States
    
    07/944,739
    
    5,374,657
    
    Granted 20 Dec 9408/358,474
    
    5,550,156
    
    Granted 27 Aug 96
   Page 30 of 46




---



##### 



Arachidonic Acid and Methods for the Production and Use Thereof
 Country
    
    Application No.
    
    Publ. or Patent No.
    
    StatusAustralia
    
    AU92/12355
    
    661,674
    
    Granted 21 Nov 95AU96/48542
    
    713,567
    
    Granted 16 Mar 00*
    
    *
    
    
    
    *Canada
    
    2,101,273
    
    2,101,273
    
    Granted 2 Apr 022,209,513
    
    2,209,513
    
    Granted 28 May 02China
    
    96192002.5
    
    CN1175976A
    
    Published 11 Mar 98200510071295.2
    
    CN1696300A
    
    Published 16 Nov 05Eurasia
    
    97-0090US
    
    EA1036
    
    Granted 28 Aug 00Europe(validated in Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands,
Portugal, Spain, Sweden,
Switzerland/
Liechtenstein, and
United Kingdom)
    
    96904435.3
    
    EP0 800 584
    
    Granted 2 May 03(Opposition Pending)(designates same
countries as
parent)
    
    03076254.6
    
    EP1 342 787A1(Div of EP0 800 584)
    
    Published 10 Sep 03(designates
Austria, Belgium,
Denmark, France,
Germany, Greece,
Italy, Luxembourg,
Monaco,
Netherlands, Spain,
Sweden, Switzerland/L
iechtenstein and
United Kingdom)
    
    05 077139.3
    
    EP1 642 983B1(Div of EP1 001 034)
    
    Granted 11 Apr 07(designates same
countries as
parent)
    
    06077261.3
    
    EP1 801 226 A1(Div of EP1 642 983)
    
    Published 27 Jun 07Finland
    
    972829
    
    117442
    
    Granted 13 Oct 2006*
    
    
    
    *Hong Kong
    
    4101355.3
    
    HK 1058528A
    
    Published 21 May 0406105700.4
    
    HK 1085768
    
    Published 11 Sep 06Indonesia
    
    P-001679
    
    ID 0000393
    
    Granted 22 Dec 95Israel
    
    100,732
    
    100,732
    
    Granted 1 Oct 95Japan
    
    08-521231 (1996)
    
    1998 10512444
    
    Published 2 Dec 982005-368593
    
    2006 180877JP
    
    Published 13 Jul 06*
    
    
    
    *Mexico
    
    92/00301
    
    202940
    
    Granted 6 Jul 0197/005078
    
    234429
    
    Granted 13 Feb 06
   Page 31 of 46




---



##### 



Country
    
    Application No.
    
    Publ. or Patent No.
    
    StatusNew Zealand
    
    241,358
    
    241,358
    
    Granted 8 Feb 95Norway
    
    973085
    
    320117
    
    Granted 31 Oct 05Philippines
    
    43811
    
    1-1992-43811
    
    Granted 22 Aug 02Poland
    
    P321208
    
    187694
    
    Granted 14 Jan 04Russia
    
    93-054772
    
    2120998
    
    Granted 27 Oct 9897-0090US
    
    EA1036
    
    Granted 28 Aug 00Singapore
    
    9703038.1
    
    42669
    
    Granted 30 Mar 99(Revocation Pending)South Korea
    
    1999-7008800
    
    302036
    
    Granted 29 Jun 01(Opposition Pending)2006-7015060
    
    6096168A
    
    Published 7 Jun 06South Africa
    
    92/0454
    
    92/0454
    
    Granted 28 Oct 92Sri Lanka
    
    10527
    
    10527
    
    Granted 27 Oct 93United States
    
    08/367,881
    
    5,658,767
    
    Granted 19 Aug 97
   Page 32 of 46




---



##### 



Docosahexaenoic Acid, Methods for its Production
and Compounds Containing the Same
 Country
    
    Application No.
    
    Publ. or Patent No.
    
    StatusAustralia
    
    AU91/73302
    
    660,162
    
    Granted 03 Oct 95*
    
    *
    
    
    
    *Canada
    
    2,076,018
    
    2,076,018
    
    Granted 2 May 00Europe (validated in Austria, Belgium,
Denmark, France,
Germany, Greece,
Italy, Luxembourg,
Netherlands, Spain,
Sweden,
Switzerland/
Liechtenstein, and
United
Kingdom)
    
    91903945.3
    
    EP0 515 460
    
    Granted 22 Apr 1998(Opposition Pending)Israel
    
    97,126
    
    97,126
    
    Granted 16 Jun 95111,174
    
    111,174
    
    Granted 11 Jun 98Japan
    
    1991-504147
    
    2830951
    
    Granted 25 Sep 981998-177561
    
    11-092783
    
    Published 24 Jun 19982003-27974
    
    3957196
    
    Granted 18 May 072004-57293
    
    2004-215668
    
    Published 5 Aug 20042005-09518
    
    2005-176851
    
    Published 5 Jul 20052006-017013
    
    2006-191931
    
    Published 27 Jul 20062007-41363
    
    2007-195556
    
    Published 9 Aug 2007Philippines
    
    I 41991
    
    31568
    
    Granted 3 Nov 98I 54562
    
    1-1996-54562
    
    Granted 26 May 03I 54563
    
    1-1996-54563
    
    Granted 5 Aug 03Romania
    
    98-20074
    
    2.079T
    
    Granted 30 Jan 2001South Korea
    
    91-701943
    
    285870
    
    Granted 8 Jan 0110-1999-7011087
    
    294293
    
    Granted 13 Apr 01United States
    
    07/916,874
    
    5,397,591
    
    Granted 14 Mar 9507/479,135
    
    5,407,957
    
    Granted 18 Apr 9508/386,079
    
    5,492,938
    
    Granted 20 Feb 9608/583,845
    
    5,711,983
    
    Granted 27 Jan 98
  -33-




---



##### 



EXHIBIT 2  SPECIFICATIONS
 ARASCO ®
 Product Specifications
 General Characteristics
 Description:     Vegetable oil from fungi, containing 40% arachidonic acid (ARA) 
Appearance:    Free flowing yellow liquid oil (triglyceride) 
Odor:                 Characteristic 
Antioxidants:  *
 Chemical Characteristics
    
    Fatty Acid Composition
    
    Area %*
Free Fatty Acid    < 0.4%
    
    **Elemental Composition **Product Storage and Stability
   Ingredients
   -34-




---



##### 



DHASCO ®
 Product Specifications
 General Characteristics
 Description:
    
    Vegetable oil from microalgae, containing 40% docosahexaenoic acid (DHA)Appearance:
    
    Free flowing light yellow to dark orange liquid oil (triglyceride)Odor:
    
    CharacteristicAntioxidants:
    
    *
 Chemical Characteristics
    
    Fatty Acid Composition
    
    Area %*Free Fatty Acid < 0.4%
    
    **Elemental Composition**
 Product Storage and Stability
   Ingredients
   -35-




---



##### 



EXHIBIT 3  TERRITORY
  From the 1992 License Agreement (as amended)
  From the 2003 INC A/S License Agreement (as amended)
 From the 2003 INC * Agreement
  -36-




---



##### 



EXHIBIT 4  PRICING
 Exhibit 4
  Exhibit 4
 Exhibit 4
  -37-




---



##### 



*(
 *
 Annual Volume
    
    Price per Unit of
    
    Annual Volume
    
    Price per Kilogram(Units)
    
    Martek Products
    
    (Kilograms)
    
    of Martek Products*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
 Conditions
 1.
    
    Martek Products for which * must comprise one hundred percent (100%) of any and all
Omega-3 and Omega-6 LCPUFAs contained in any quantity of any Infant Formula Products made
using such Martek Products.2.
    
    The ratio of ARA to DHA in any Infant Formula Product made using the Martek Products
shall be no greater than *.
 *:
 Annual Volume
    
    Price per Unit of
    
    Annual Volume
    
    Price per Kilogram(Units)
    
    Martek Products
    
    (Kilograms)
    
    of Martek Products*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
  -38-




---



##### 



Conditions
 1.
    
    Martek Products for which * must comprise one hundred percent (100%) of any and all
Omega-6 LCPUFAs contained in any quantity of any Infant Formula Products made using such
Martek Products, and all Omega-3 LCPUFAs contained therein which are not Martek Products
must be derived from non-microbial sources.
 *:
 Annual Volume
    
    Price per Unit of
    
    Annual Volume
    
    Price per Kilogram(Units)
    
    Martek Products
    
    (Kilograms)
    
    of Martek Products*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
 Conditions
 1.
    
    Martek Products for which * must comprise one hundred percent (100%) of any and all
Omega-6 LCPUFAs contained in any quantity of any Infant Formula Products made using such
Martek Products, and all Omega-3 LCPUFAs contained therein which are not Martek Products
must be derived from non-microbial sources.
 *:
 Annual Volume
    
    Price per Unit of
    
    Annual Volume
    
    Price per Kilogram(Units)
    
    Martek Products
    
    (Kilograms)
    
    of Martek Products*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
  -39-




---



##### 



Conditions
 1.
    
    Martek Products for which * must comprise one hundred percent (100%) of any and all
Omega-3 and Omega-6 LCPUFAs contained in any quantity of any Infant Formula Products made
using such Martek Products.2.
    
    The ratio of ARA to DHA in any Infant Formula Product made using the Martek Products
shall be no greater than *.
 *:
 Annual Volume
    
    Price per Unit of
    
    Annual Volume
    
    Price per Kilogram(Units)
    
    Martek Products
    
    (Kilograms)
    
    of Martek Products*
    
    *
    
    *
    
    **
    
    *
    
    *
    
    *
 Conditions
 1.
    
    Martek Products for which * must only be used in Growing Up Milk Products.
  -40-




---



##### 



EXHIBIT 5  PRESS RELEASE
 For Immediate Release
    
    Contact:Cassie France-KellyPublic Relations(443) 542-2116media@martek.comKyle StultsInvestor Relations(410) 740-0081investors@martek.com
 Martek Signs Multi-Year Sole-Source Supply Agreement with Numico
 COLUMBIA, Md  DATE TBD 
  lifesDHA lifesARA
  -41-




---



##### 



lifesDHA lifesARA
  lifesDHA lifesARA http://www.martek.com
   -42-




---



##### 



EXHIBIT 6
 *
 *
  -43-




---



##### 



EXHIBIT 7
  Country
    
    License Fee (USD)*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
  -44-




---



##### 



Country
    
    License Fee (USD)*
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    **
    
    *
   -45-




---



##### 



EXHIBIT 8
  -46-